The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Global mapping of pharmacological space
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Self-citationLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Self-citationKnowledge Discovery in Databases
Piateski, G., & Frawley, W. (1991) · The MIT Press eBooks · Cited by 1,749
Simple Selection Criteria for Drug-like Chemical Matter
Muegge, I., Heald, S. L., & Brittelli, D. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015507e · Cited by 1,315
Database Systems: A Practical Approach to Design, Implementation and Management
Connolly, T. M., & Begg, C. E. (1998) · Cited by 1,243
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Self-citationChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Self-citationA comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“Repositioning drugs might be successful due to the possibility of multiple-target involvement in multiple diseases [267–269].”
BackgroundDrug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Hopkins, A. L. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1110 · Cited by 1,242
Self-citationThe role of ligand efficiency metrics in drug discovery
Hopkins, A. L., Keserü, G. M., Leeson, P. D., Rees, D. C., & Reynolds, C. H. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4163 · Cited by 1,181
Self-citationMulti-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Target identification and mechanism of action in chemical biology and drug discovery
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1199 · Cited by 1,096
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945
“Indeed, a recent global analysis of conventional screening data for nearly five million nonredundant structures collected over 25 years in both industry and academia found that the total number of human proteins for which chemical tools have been discovered so far is just 836 (Ref”
BackgroundStructure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Large-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
Automated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832
“In principle the approach is applicable to all drug target classes limited only by the requirement for sufficient structure-activity (SAR) data to create useful models 9-12 .”
BackgroundSelf-citationOral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Beck, B. R., Shin, B., Choi, Y., Park, S., & Kang, K. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.025 · Cited by 816
Halogen atoms in the modern medicinal chemistry: hints for the drug design
Hernandes, M., Cavalcanti, S. M., Moreira, D. R., de Azevedo Junior, W., & Leite, A. C. (2010) · Current Drug Targets · doi:10.2174/138945010790711996 · Cited by 723
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707305 · Cited by 703
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
STITCH 4: integration of protein–chemical interactions with user data
Kuhn, M., Szklarczyk, D., Pletscher-Frankild, S., Blicher, T. H., von Mering, C., Jensen, L. J., & Bork, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1207 · Cited by 487
Shifting from the single to the multitarget paradigm in drug discovery
Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.008 · Cited by 483
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Big data and artificial intelligence modeling for drug discovery
Zhu, H. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023324 · Cited by 455
“In an early review of pharmacological space based on 4.8 million unique compounds, only 275,000 of them showed one (or more) active response when tested against 1,036 targets (55), indicating that most of the testing results were negative.”
BackgroundInfluentialNatural Organic Matter and the Event Horizon of Mass Spectrometry
Hertkorn, N., Frommberger, M., Witt, M., Koch, B. P., Schmitt-Kopplin, P., & Perdue, E. M. (2008) · Analytical Chemistry · doi:10.1021/ac800464g · Cited by 455
Yu, H., Chen, J., Xu, X., Li, Y., Zhao, H., Fang, Y., Li, X., Zhou, W., Wang, W., & Wang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037608 · Cited by 423
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
In silico pharmacology for drug discovery: applications to targets and beyond
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707306 · Cited by 365
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Network‐based Approaches in Pharmacology
Boezio, B., Audouze, K., Ducrot, P., & Taboureau, O. (2017) · Molecular Informatics · doi:10.1002/minf.201700048 · Cited by 359
Comprehensive characterization of the Published Kinase Inhibitor Set
Elkins, J. M., Fedele, V., Szklarz, M., Abdul Azeez, K. R., Salah, E., Mikolajczyk, J., Romanov, S., Sepetov, N., Huang, X.-P., Roth, B. L., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3374 · Cited by 323
Unveiling the role of network and systems biology in drug discovery
Pujol, A., Mosca, R., Farrés, J., & Aloy, P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.006 · Cited by 346
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
Alex, A., Millan, D. S., Perez, M., Wakenhut, F., & Whitlock, G. A. (2011) · MedChemComm · doi:10.1039/c1md00093d · Cited by 329
Computational/in silico methods in drug target and lead prediction
Agamah, F. E., Mazandu, G. K., Hassan, R., Bope, C. D., Thomford, N. E., Ghansah, A., & Chimusa, E. R. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz103 · Cited by 328
Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., Urban, L., Whitebread, S., & Jenkins, J. L. (2007) · ChemMedChem · doi:10.1002/cmdc.200700026 · Cited by 327
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Kinnings, S. L., Liu, N., Buchmeier, N., Tonge, P. J., Xie, L., & Bourne, P. E. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000423 · Cited by 319
Comparability of Mixed IC50 Data – A Statistical Analysis
Kalliokoski, T., Kramer, C., Vulpetti, A., & Gedeck, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061007 · Cited by 315
Metz, J. T., Johnson, E. F., Soni, N. B., Merta, P. J., Kifle, L., & Hajduk, P. J. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.530 · Cited by 311
Genomic-scale prioritization of drug targets: the TDR Targets database
Agüero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F. S., Campbell, R. K., Carmona, S., Carruthers, I. M., Chan, A. W. E., Chen, F., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2684 · Cited by 306
Self-citationCell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
In silico clinical trials: how computer simulation will transform the biomedical industry
Viceconti, M., Henney, A., & Morley-Fletcher, E. (2016) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20161408 · Cited by 289
In silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 288
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., et al. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.05.011 · Cited by 287
Network-Based Relating Pharmacological and Genomic Spaces for Drug Target Identification
Zhao, S., & Li, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011764 · Cited by 277
Chemogenomic approaches to rational drug design
Rognan, D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707307 · Cited by 269
Data completeness—the Achilles heel of drug-target networks
Mestres, J., Gregori-Puigjané, E., Valverde, S., & Solé, R. V. (2008) · Nature Biotechnology · doi:10.1038/nbt0908-983 · Cited by 265
Active-learning strategies in computer-assisted drug discovery
Reker, D., & Schneider, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.004 · Cited by 261
Bioinformatics challenges for personalized medicine
Fernald, G. H., Capriotti, E., Daneshjou, R., Karczewski, K. J., & Altman, R. B. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr295 · Cited by 258
Applications of Connectivity Map in drug discovery and development
Qu, X. A., & Rajpal, D. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.017 · Cited by 235
Artificial Intelligence for Drug Discovery: Are We There Yet?
Hasselgren, C., & Oprea, T. I. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-040323-040828 · Cited by 236
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Comprehensive prediction of drug-protein interactions and side effects for the human proteome
Zhou, H., Gao, M., & Skolnick, J. (2015) · Scientific Reports · doi:10.1038/srep11090 · Cited by 138
Gao, J., Mfuh, A., Amako, Y., & Woo, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11639 · Cited by 102
Linking Phenotypes and Modes of Action Through High-Content Screen Fingerprints
Reisen, F., Sauty de Chalon, A., Pfeifer, M., Zhang, X., Gabriel, D., & Selzer, P. (2015) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2015.656 · Cited by 76
Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control
Wang, Y., Kirschner, A., Fabian, A.-K., Gopalakrishnan, R., Kress, C., Hoogeland, B., Koch, U., Kozany, C., Bracher, A., & Hausch, F. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400087k · Cited by 60
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Tutorial on Drug Development for Central Nervous System
Yoon, H.-J., & Kim, J.-S. (2010) · Interdisciplinary Bio Central · doi:10.4051/ibc.2010.2.4.0009 · Cited by 1
Metadata
- Authors
- Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L.
- Venue
- Nature Biotechnology
- Published
- 2006-07-01
- Volume
- 24
- Issue
- 7
- Pages
- 805-815
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1972821149
- Cited by
- 811
- References
- 53
- FWCI
- 52.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.